Compare Southern Copper Corp (SCCO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southern Copper Corp vs Zimmer Biomet Holdings Inc — how do they compare? Southern Copper Corp trades at $209.39 (market cap $167.74B), while Zimmer Biomet Holdings Inc trades at $89.39 (market cap $16.95B). The key difference: Southern Copper Corp is far larger — about 9.9× Zimmer Biomet Holdings Inc's market cap, and Southern Copper Corp pays the higher dividend (2.21%). Which is the better fit depends on your goals — on Pluang, investors hold Southern Copper Corp for 61 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SCCO | ZBH | |
|---|---|---|
Market Cap | $167.74B | $16.95B |
Volume | 853,110 | 2,505,240 |
Sector | Basic Materials | Health |
52-Week High | $219.70 | $103.98 |
52-Week Low | $120.02 | $79.58 |
Typical Hold Time | 61 Days | 89 Days |
Enterprise Value | $169.03B | $24.02B |
Dividend Yield | 2.21% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southern Copper (SCCO) trades at $208.31, up 3.86% over the past day, but remains below the consensus price target of $167.67. The stock shows strong fundamentals with revenue rising to $13.42B in 2025 and net income reaching $4.33B, though valuation ratios like a P/E of 29.81 and P/S of 10.72 appear elevated. Recent earnings beats and a bullish long-term growth outlook from projects like the $10.2B Mexican pipeline contrast with a bearish technical signal and mixed analyst sentiment.
SCCO presents a cautious outlook due to high valuations and bearish technicals, but robust profitability and expansion projects offer growth potential. Key risks include reliance on copper prices and competitive pressures, while institutional activity shows divided interest. Investors should weigh strong cash flows against premium pricing before entry.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
